Eribulin Mesylate
Generic Name: eribulin mesylate
Brand Names:
Eribulin Mesylate
Eribulin mesylate is a prescription microtubule dynamics inhibitor, a synthetic analog of halichondrin B, available as 0.5 mg/mL injection for cancer treatment.
Overview
Eribulin mesylate is a prescription microtubule dynamics inhibitor, a synthetic analog of halichondrin B, available as 0.5 mg/mL injection for cancer treatment.
Uses
Indicated for metastatic breast cancer patients who previously received at least two chemotherapy regimens (including anthracycline and taxane), and unresectable or metastatic liposarcoma in patients with prior anthracycline treatment.
Dosage
Standard dose is 1.4 mg/m2 intravenously over 2-5 minutes on Days 1 and 8 of a 21-day cycle. Reduced doses recommended for hepatic or renal impairment.
Side Effects
Most common effects include neutropenia, anemia, fatigue, alopecia, peripheral neuropathy, nausea, and constipation. Serious reactions include febrile neutropenia and severe peripheral neuropathy.
Interactions
No clinically meaningful interactions with CYP3A4 inhibitors, inducers, or P-glycoprotein inhibitors.
Warnings
Monitor for neutropenia, peripheral neuropathy, embryo-fetal toxicity, and QT prolongation. Contraindicated in congenital long QT syndrome.
Pregnancy
Can cause fetal harm. Animal studies showed embryo-fetal toxicity at doses below recommended human dose.
Storage
Store at 20-25 degrees C. Do not freeze or refrigerate. Maintain in original cartons.
Frequently Asked Questions
What is Eribulin Mesylate used for?▼
Indicated for metastatic breast cancer patients who previously received at least two chemotherapy regimens (including anthracycline and taxane), and unresectable or metastatic liposarcoma in patients with prior anthracycline treatment.
What are the side effects of Eribulin Mesylate?▼
Most common effects include neutropenia, anemia, fatigue, alopecia, peripheral neuropathy, nausea, and constipation. Serious reactions include febrile neutropenia and severe peripheral neuropathy.
Can I take Eribulin Mesylate during pregnancy?▼
Can cause fetal harm. Animal studies showed embryo-fetal toxicity at doses below recommended human dose.
What are the important warnings for Eribulin Mesylate?▼
Monitor for neutropenia, peripheral neuropathy, embryo-fetal toxicity, and QT prolongation. Contraindicated in congenital long QT syndrome.
Related Medications
Drospirenone And Estetrol
drospirenone and estetrol
11 DESCRIPTION NEXTSTELLIS ® (drospirenone and estetrol tablets) is an oral contraceptive. It is supplied in a transparent PVC/aluminum blister card containing 28 tablets: 24 pink active tablets contain 3 mg drospirenone and 14.2 mg of estetrol on the anhydrous basis. Drospirenone is a synthetic progestin and estetrol is a synthetic estrogen. 4 white inert tablets. The chemical name for estetrol is estra-1,3,5(10)-triene-3,15α,16α,17α-tetrol monohydrate.
Metformin Hydrochloride Extended-release Tablets
metformin hydrochloride extended-release tablets
11 DESCRIPTION Metformin hydrochloride extended-release tablets contain the biguanidine antihyperglycemic agent, metformin, in the form of monohydrochloride salt. The chemical name of metformin HCl is N, N-dimethylimidodicarbonimidic diamide hydrochloride with a molecular formula of C 4 H 11 N 5 •HCl and a molecular weight of 165.63.
Febuxostat
febuxostat
Xanthine Oxidase Inhibitor [EPC]
Febuxostat is a xanthine oxidase inhibitor for chronic management of hyperuricemia in adult gout patients.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.